KEY OPINION LEADERS

Find out who has spoken at Galien Foundation
meetings and events

We are determined to ensure that Galien Foundation events are second-to-none in caliber. Our forums, meetings and digital events bring together the world’s thought leaders in one singular mission - to improve the human condition. Discover who has spoken at our events by searching below.

Image 81-1
Who are you looking for?
Image 81-1
NAME COMPANY TITLE EVENT TOPIC COUNTRY
2022 Roderick Van Grieken Nederlands Debat Instituut Prix Galien Netherlands 2022 Netherlands
2022 Nicky Hekster Dr Prix Galien Netherlands 2022 Netherlands
2022 Koos Burggraaf Prof Prix Galien Netherlands 2022 Netherlands
2022 Marc Bonten Prof Prix Galien Netherlands 2022 Netherlands
2022 Lisette Van Gemert Prof, Dr Prix Galien Netherlands 2022 Netherlands
2022 Mark Walport Prof. Sir. Chair Galien Forum UK 2022 UK
2022 Mel Walker BioPharma Futures Dr. Moderator Biotech/Digital Health Adviser Galien Forum UK 2022 (PANEL 2) ACCESS TO INNOVATION: OPTIMIZING HEALTH FOR PATIENT POPULATIONS UK
2022 Andy Richards Congenica Ltd, Owlstone Medical, Closed Loop Medicine and Ieso Digital Health Dr. CBE I Chair Galien Forum UK 2022 (PANEL 3) DIGITAL HEALTH INNOVATION: A KEY DRIVER OF NEXT GENERATION HEALTHCARE – WHAT AND WHEN? UK
2020 Ted Johnson Pfizer Oncology Pfizer Inc Research Fellow, Medicinal Chemistry Galien Week of innovation What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation? USA
2020 Ute Simon AAA (a Novartis company) Head Global Medical Affairs Galien Week of innovation What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation? USA
2020 Santosh Prabhu Abbott Structural Heart Divisional Vice President, Product Development Galien Week of innovation How much are new technologies and engineering efficiencies contributing to progress against the world’s biggest killer? USA
2020 Sailaja Bhaskar Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P. Executive Director, Clinical Operations Planning Galien Week of innovation The ability to claim larger health system productivity benefits from the introduction of chronic disease medicines looms in importance as these therapeutic segments become more crowded and competitive. USA
2020 Pushkal Garg Alnylam Chief Medical Officer Galien Week of innovation Will progress in therapies that promise a genetic cure for devastating rare diseases lead to similar innovations in patient access to these highcost, high-touch treatments? USA
2020 Ponda Motsepe – Ditshego Amgen Bone Executive Medical Director Galien Week of innovation Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions? USA
2020 Cen Xu Amgen Neuroscience Executive Director Galien Week of innovation Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions? USA
2020 Roy Wiesner aMoon Managing Director Galien Webinars The Digital Health Enterprise: Start-Up Trends and the Culture of Big Pharma USA
2020 Ramon Tiu Astellas Pharma Inc. Executive Medical Director, Astellas Pharma Global Development Global Medical Leader, Gilteritinib Program Galien Week of innovation Are there common links in advancing research on hematologic cancers and other rare diseases associated with uncontrolled vascular system inflammation, such as sickle cell anemia? USA
2022 Menelas (Mene) Pangalos AstraZeneca Prof. Sir. EVP & President BioPharmaceuticals R&D Galien Forum UK 2022 (PANEL 1) CLINICAL TRIALS & REGULATIONS: WHAT HAVE WE LEARNED FROM COVID? UK
2020 Marc Fellous Bayer Global Medical Affairs Head Galien Week of innovation What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation? USA
2020 Jorge Ortiz Bayer Global Medical Affairs Head Galien Week of innovation What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation? USA
2020 Jessica Federer Bayer Partner Boston Millenia Partners Former CDO Galien Webinars Digital Health Improving Research and Care USA
2020 Michael Ringel BCG Managing Director and Senior Partner Galien Week of innovation Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to other conditions? USA
2022 Myrto Lee BCG Dr. Moderator. Managing Director & Partner Galien Forum UK 2022 (PANEL 1) CLINICAL TRIALS & REGULATIONS: WHAT HAVE WE LEARNED FROM COVID? UK
2020 Stephanie Klocke Becton, Dickinson and Company Vice President of Research & Development Galien Week of innovation What is MedTech innovation doing for patients with specialized needs for treatment? USA
2020 David Hayes Biotronik Chief Medical Officer Galien Week of innovation How much are new technologies and engineering efficiencies contributing to progress against the world’s biggest killer? USA
2020 Shwen Gwee Bristol Myers Squibb VP and Head of Global Digital Strategy Galien Webinars Digital Health in the Aftermath of COVID-19 USA
2020 Kate Rosenbluth Cala Health Founding CEO & CSO Galien Week of innovation How far are we from achieving the health system world of the connected patient? USA
2020 Angela Radcliffe CAPGEMINI INVENT R&D Practice Lead,m Founding Member, CoS, IEEE Global Initiative to Standardize Fairness in the Trade of Data; Advisory Board Member to Startups in Life Science; Clinical Research Advocate Galien Webinars The Digital Health Enterprise: Start-Up Trends and the Culture of Big Pharma USA
2020 Milind Kamkolkar CELLARITY Chief Digital & Data Officer Galien Webinars The Digital Health Enterprise: Start-Up Trends and the Culture of Big Pharma USA
2022 Catherine Pollard Centre for Improving Data Collaboration, NHSX Director Galien Forum UK 2022 (PANEL 3) DIGITAL HEALTH INNOVATION: A KEY DRIVER OF NEXT GENERATION HEALTHCARE – WHAT AND WHEN? UK
2020 Barbara Fant Clinical Research Consultants, Inc. President Galien Week of innovation How far are we from achieving the health system world of the connected patient? USA
2020 Dr. Amir Kalali CNS Summit CO Chair, Decentralized Trials & Researched Alliance; Chief Currator and Chairman Galien Webinars Digital Health in the Aftermath of COVID-19 USA
2020 Javad Shahidi Daiichi Sankyo Vice President, Global Oncology R&D Galien Week of innovation Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to other conditions? USA
2020 Uri Bettesh Datos-Health CEO Galien Webinars Digital Health in the Aftermath of COVID-19 USA
2022 Vishal Gulati Deeptech / Healthtech VC Dr. Galien Forum UK 2022 (PANEL 3) DIGITAL HEALTH INNOVATION: A KEY DRIVER OF NEXT GENERATION HEALTHCARE – WHAT AND WHEN? UK
2020 Flavio Manetlli Dompé U.S. Inc. Chief Medical officer Galien Week of innovation Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to other conditions? USA
2020 Satasuk Joy Bhosai Duke Clinical Research Institute Chief of Digital Health and Strategy Galien Webinars Digital Health Improving Research and Care USA
2020 Brian S. Conklin Edwards Lifesciences Senior Distinguished Engineer Galien Week of innovation How much are new technologies and engineering efficiencies contributing to progress against the world’s biggest killer? USA
2020 Laksen Sirimanne Edwards Lifesciences Vice President, Research & Development Galien Week of innovation How much are new technologies and engineering efficiencies contributing to progress against the world’s biggest killer? USA
2020 Eric M Pearlman Eli Lilly and Company Senior Medical Director-Migraine/Pain, Neuroscience Medical Affairs Galien Week of innovation The ability to claim larger health system productivity benefits from the introduction of chronic disease medicines looms in importance as these therapeutic segments become more crowded and competitive. USA
2020 Douglas Schlichting Eli Lilly and Company Development Director Immunology Product Development – baricitinib rheumatoid arthritis and COVID-19 Galien Week of innovation The ability to claim larger health system productivity benefits from the introduction of chronic disease medicines looms in importance as these therapeutic segments become more crowded and competitive. USA
2020 Eric M Pearlman Eli Lilly and Company Senior Medical Director-Neuroscience, US Medical Affairs Galien Week of innovation Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions? USA
2020 Dr. Eric Mayes Endomag Ltd. CEO Galien Week of innovation How far are we from achieving the health system world of the connected patient? USA
2020 Amy Abernethy FDA Principal Deputy Commissioner Galien Webinars Digital Health Improving Research and Care USA
2020 Gil Bashe Finn Partners Managing Partner, Chair Global Health Galien Webinars Digital Health in the Aftermath of COVID-19 USA
2020 Gil Bashe Finn Partners Managing Partner, Chair Global Health Galien Webinars Digital Health Webinar – Presentation of the Nominees in the 2020 Prix Galien Digital Health Category USA
2020 Gil Bashe Finn Partners Managing Partner, Chair Global Health Galien Webinars The Digital Health Enterprise: Start-Up Trends and the Culture of Big Pharma USA
2020 Michael Rosenblatt Flagship Pioneering, Cambridge, MA Chief Medical Officer Galien Week of innovation Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions? USA
2020 Jonathan Sorof Global Blood Therapeutics Senior Vice President, Head of Medical Affairs Galien Week of innovation Will progress in therapies that promise a genetic cure for devastating rare diseases lead to similar innovations in patient access to these highcost, high-touch treatments? USA
2022 Patrick Vallance Government Sir. Government Chief Scientific Adviser Galien Forum UK 2022 (PANEL 2) ACCESS TO INNOVATION: OPTIMIZING HEALTH FOR PATIENT POPULATIONS UK
2022 Christopher Corsico GSK Dr. Global Head of Development Galien Forum UK 2022 (PANEL 1) CLINICAL TRIALS & REGULATIONS: WHAT HAVE WE LEARNED FROM COVID? UK
2021 Michal Rosen-Zvi IBM, Health Informatics Director of Health Informatics JEF 2021 ARTIFICIAL INTELLIGENCE AND ETHICS Israël
2022 Andy Blackwell Ieso Digital Health Dr. Chief Science and Strategy Officer Galien Forum UK 2022 (PANEL 3) DIGITAL HEALTH INNOVATION: A KEY DRIVER OF NEXT GENERATION HEALTHCARE – WHAT AND WHEN? UK
2020 Ishu Rao Impulse Dynamics Medical Director Galien Week of innovation How much are new technologies and engineering efficiencies contributing to progress against the world’s biggest killer? USA
2020 MaryAnne Rizk IQVIA Senior Vice President, R&D Digital Strategy Galien Week of innovation Will the coronavirus pandemic finally lead to an upswing in R&D to tackle neglected areas like antibiotic resistance, zoonotic transmission of pathogens and a more globally-coordinated approach to infectious diseases overall? USA
2020 Dan Cua Janssen Biotech, Inc. Vice President IL-23 Pathway Area Leader for the Immunology Therapeutic Area Galien Week of innovation Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions? USA
2020 Sabine Brookman-May Janssen Research & Development, LLC Executive Medical Director, Late Development, Solid Tumor Galien Week of innovation What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation? USA
2020 Sam Spigelman Janssen Research & Development, LLC Senior Global Medical Affairs Leader Galien Week of innovation What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation? USA
2020 Michael Michael Karyopharm Therapeutics Inc Chief Executive Officer Co-Founder Galien Week of innovation Are there common links in advancing research on hematologic cancers and other rare diseases associated with uncontrolled vascular system inflammation, such as sickle cell anemia? USA
2020 Steven J. Lester Mayo Clinic-ASU MedTech Accelerator Chief Medical Officer Galien Week of innovation How much are new technologies and engineering efficiencies contributing to progress against the world’s biggest killer? USA
2022 Alison Holland Medable Head of Decentralized Clinical Trials Galien Forum UK 2022 (PANEL 1) CLINICAL TRIALS & REGULATIONS: WHAT HAVE WE LEARNED FROM COVID? UK
2020 Mark Sullivan Medicines Development for Global Health Founder and Managing Director Galien Week of innovation Will the coronavirus pandemic finally lead to an upswing in R&D to tackle neglected areas like antibiotic resistance, zoonotic transmission of pathogens and a more globally-coordinated approach to infectious diseases overall? USA
2022 Carole Longson Medicines Discovery Catapult Prof. Vice Chair Galien Forum UK 2022 (PANEL 2) ACCESS TO INNOVATION: OPTIMIZING HEALTH FOR PATIENT POPULATIONS UK
2020 Jessica Grossman Medicines360 CEO Galien Week of innovation Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions? USA
2020 Robert Kowal Medtronic Chief Medical Officer, Vice President of Medical Affairs & Business Development Galien Week of innovation How much are new technologies and engineering efficiencies contributing to progress against the world’s biggest killer? USA
2020 Beth-Ann Coller Merck & Co., Inc Executive Director, Global Clinical Development Galien Week of innovation Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to other conditions? USA
2020 Amanda Paschke Merck & Co., Inc. Executive Director Global Clinical Development Galien Week of innovation Will the coronavirus pandemic finally lead to an upswing in R&D to tackle neglected areas like antibiotic resistance, zoonotic transmission of pathogens and a more globally-coordinated approach to infectious diseases overall? USA
2022 Dame June Raine MHRA CEO Galien Forum UK 2022 (PANEL 1) CLINICAL TRIALS & REGULATIONS: WHAT HAVE WE LEARNED FROM COVID? UK
2020 Junaid Bajwa Microsoft Chief Medical Scientist Galien Webinars Digital Health in the Aftermath of COVID-19 USA
2020 Robert S. Langer MIT David H. Koch Institute Professor Galien Week of innovation What is MedTech innovation doing for patients with specialized needs for treatment? USA
2020 Jane Metcalfe Neo.Life. Wired Magazine CEO, Co-Founder Galien Webinars Digital Health in the Aftermath of COVID-19 USA
2022 David Prior NHS England Lord. Chair Galien Forum UK 2022 (PANEL 2) ACCESS TO INNOVATION: OPTIMIZING HEALTH FOR PATIENT POPULATIONS UK
2020 Mimi Huizinga Novartis Vice President and HeaS Oncology Medical Galien Week of innovation Are there common links in advancing research on hematologic cancers and other rare diseases associated with uncontrolled vascular system inflammation, such as sickle cell anemia? USA
2020 Mimi Huizinga Novartis Vice President and Head, US Oncology Medical Galien Week of innovation What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation? USA
2020 David J. Lennon Novartis Gene Therapies President Galien Week of innovation Will progress in therapies that promise a genetic cure for devastating rare diseases lead to similar innovations in patient access to these highcost, high-touch treatments? USA
2020 David Platt Novartis Pharmaceuticals Corporation Vice President, Medical Unit Head Cardiovascular, Renal & Metabolism Medical Unit Galien Week of innovation The ability to claim larger health system productivity benefits from the introduction of chronic disease medicines looms in importance as these therapeutic segments become more crowded and competitive. USA
2020 Mads Frederik Rasmussen Novo Nordisk A/S Corporate Project Vice President (CPVP) for GLP-1, CV and Outcomes Galien Week of innovation Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions? USA
2020 Katherine Vandebelt Oracle Health Science Global Vice President, Clinical Innovation Galien Week of innovation The ability to claim larger health system productivity benefits from the introduction of chronic disease medicines looms in importance as these therapeutic segments become more crowded and competitive. USA
2022 Martin Landray Oxford University Prof. Sir. Professor of Medicine and Epidemiology Galien Forum UK 2022 (PANEL 1) CLINICAL TRIALS & REGULATIONS: WHAT HAVE WE LEARNED FROM COVID? UK
2020 Michelle Hoiseth Parexel International Chief Data Officer & Corporate VP Medical and Scientific Services Galien Webinars Digital Health Improving Research and Care USA
2020 Yuri Maricich Pear Therapeutics Chief Medical Officer & Head of Development Galien Week of innovation How far are we from achieving the health system world of the connected patient? USA
2020 Sandi See Tai Pfizer Global Product Development Pfizer Inc. VP, Medicine Team Lead for Amyloid, Rare Neuro & Cardiac Galien Week of innovation The ability to claim larger health system productivity benefits from the introduction of chronic disease medicines looms in importance as these therapeutic segments become more crowded and competitive. USA
2020 Sri Radhakrishnan Pulmonx Corporation Chief Technical Officer Galien Week of innovation What is MedTech innovation doing for patients with specialized needs for treatment? USA
2020 Marcella Ruddy Regeneron Vice President, Strategic Program Direction, Immunology and Inflammation Galien Week of innovation Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions? USA
2020 Bernard Delaey Sanofi Regulatory Therapeutic Area Lead Galien Week of innovation Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to other conditions? USA
2020 Tanya Lewis Scientific American Associate Editor for Health and Medicine Galien Week of innovation Will progress in therapies that promise a genetic cure for devastating rare diseases lead to similar innovations in patient access to these highcost, high-touch treatments? USA
2020 Dennis Hruby SIGA Technologies, Inc. Chief Scientific Officer Galien Week of innovation Will the coronavirus pandemic finally lead to an upswing in R&D to tackle neglected areas like antibiotic resistance, zoonotic transmission of pathogens and a more globally-coordinated approach to infectious diseases overall? USA
2020 Theodore F. Search Skipta Chief Executive Officer Galien Week of innovation Are there common links in advancing research on hematologic cancers and other rare diseases associated with uncontrolled vascular system inflammation, such as sickle cell anemia? USA
2020 Theodore F. Search Skipta Chief Executive Officer Galien Week of innovation What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation? USA
2020 Bjarne Bergheim Sonendo, Inc President and Chief Executive Officer Galien Week of innovation What is MedTech innovation doing for patients with specialized needs for treatment? USA
2020 Eugene Kandel Start Up Nation Central CEO Galien Webinars Digital Health in the Aftermath of COVID-19 USA
2020 Dan Sexton Takeda Pharmaceutical Company Limited Strategy Lead Galien Week of innovation Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to other conditions? USA
2020 Daniel Everitt TB Alliance Vice President and Chief Medical Officer Galien Week of innovation Will the coronavirus pandemic finally lead to an upswing in R&D to tackle neglected areas like antibiotic resistance, zoonotic transmission of pathogens and a more globally-coordinated approach to infectious diseases overall? USA
2020 Mark Milton-Edwards Teva Pharmaceutical Industries Head of Product & Health Solutions – Digital Health Galien Week of innovation How far are we from achieving the health system world of the connected patient? USA
2020 Alon Iron THERANICA President & CEO, Co-founder Galien Webinars The Digital Health Enterprise: Start-Up Trends and the Culture of Big Pharma USA
2020 Susannah Fox U.S. Department of Health and Human Services Independent Consultant and Health Care Innovation Leader & Former Chief Technology Officer Galien Week of innovation How far are we from achieving the health system world of the connected patient? USA
2020 Hilary Malone Valo Health Chief Operating Officer Galien Webinars Digital Health Improving Research and Care USA
2020 Tal Wenderow VOCALIS HEALTH CEO Galien Webinars The Digital Health Enterprise: Start-Up Trends and the Culture of Big Pharma USA
2022 Samantha Roberts NICE Dr. CEO Galien Forum UK 2022 (PANEL 2) ACCESS TO INNOVATION: OPTIMIZING HEALTH FOR PATIENT POPULATIONS UK
2021 Emmanuel Fombu Medical Futurist JEF 2021 ARTIFICIAL INTELLIGENCE AND ETHICS Israël
2021 Ayman  Salem Neurosurgeon JEF 2021 ARTIFICIAL INTELLIGENCE AND ETHICS Israël
ColImage

TOP SCIENTISTS & KOL

Interested in seeing who has spoken at our events? Check out our impressive roster of Top Scientists and Key Opinion Leaders.

SEE WHO HAS SPOKEN